About Oral Mucositis

Oral Mucositis (OM): A serious complication for your patients

A painful inflammatory condition that worsens over time and can be difficult to manage1-3

Severe cases of OM may result in the interruption of a patient’s oncology treatment schedule4

Inflammation is the underlying cause

OM, an inflammation and ulceration of the mucosal membranes in the mouth and throat, is a common side effect of radiation and chemotherapy cancer treatments.1,2

SERIOUS OM COMPLICATIONS INCLUDE1-3,5:
  • Severe pain and inflammation
  • Increased risk of infections
  • Malnutrition
  • Dehydration
  • Difficulty speaking
  • Increased use of opioids

The pathogenesis of OM6*

* Adapted from J Support Oncol 2004;2(1):21–32

II&III
PHASES II & III: MESSAGING,
SIGNALING, AND AMPLIFICATION7
  • Radiation and/or chemotherapy causes direct cell death and activates second messengers, leading to upregulation in proinflammatory cytokines
  • Upregulation of proinflammatory cytokines causes injury to mucosal cells and activates pathways that amplify mucosal injury
IV
PHASE IV: ULCERATION
AND INFLAMMATION7
  • A significant inflammatory cell infiltrate is associated with the mucosal ulcerations

Well-controlled OM is essential to cancer treatment success

When radiation or chemotherapy doses must be reduced or interrupted, the efficacy of cancer therapy and patient survivorship may be compromised9,10

Severe, debilitating OM is most often associated with head and neck malignancies6
  • In one study (n = 204), OM developed in 91% of patients receiving radiation therapy, with or without chemotherapy8
  • The risk of OM was significantly higher among patients receiving a regimen of both chemotherapy and radiation versus those receiving radiation alone (P = 0.002)8

References: 1. The Joanna Briggs Institute for Evidence Based Nursing and Midwifery. Prevention and treatment of oral mucositis in cancer patients. Best Practice Evidence Based Practice Information Sheets for Health Professionals. South Australia, Australia. 1998;2(3):1-6. 2. Kintzel PE. Management of oral mucositis in cancer patients. Clin Oncol News. October 2011:1-7. 3. Silverman S Jr. Diagnosis and management of oral mucositis. Support Oncol. 2007;5(2 suppl 1):13-21. 4. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury. Cancer. 2004;100(9 suppl):1995-2025. 5. Biswal BM. Current trends in the management of oral mucositis related to cancer treatment. Malaysian J Med Sci. 2008;15(3):4-13. 6. Sonis ST. A biological approach to mucositis. J Support Oncol. 2004;2(1):21-32. 7. Lalla RV, Peterson DE. Treatment of mucositis, including new medications. Cancer J. 2006;12(5):348-354. 8. Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68(4):1110-1120. 9. Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A, Roy P. Chemotherapy-induced and/or radiation therapy-induced oral mucositis—complicating the treatment of cancer. Neoplasia. 2004;6(5)423-431. 10. Peterson DE, Cariello A. Mucosal damage: a major risk factor for severe complications after cytotoxic therapy. Semin Oncol. 2004;31(3 suppl 8):35-44.

INDICATION

GELX ORAL GEL has a mechanical action indicated for the management of pain and relief of pain, by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including: Oral Mucositis/Stomatitis (may be caused by chemotherapy or radiotherapy), irritation due to oral surgery, traumatic ulcers caused by braces or ill-fitting dentures, or disease. Also indicated for diffuse aphthous ulcers.

IMPORTANT SAFETY INFORMATION

  • GELX is contraindicated in any patient with a known history of hypersensitivity to any of the ingredients.
  • Patients should not use if stick pack has been opened prior to receipt or is damaged in any way.
  • Patients should not eat or drink for at least one hour after use.
  • If no improvement is seen in 7 days, patients are encouraged to consult their physician.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact US WorldMeds at 1-855-797-9232.
You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Please see full Prescribing Information.

GELX is a registered trademark of Sunstar Suisse SA. USWM, LLC is the exclusive licensee and distributor of GELX in the United States and Its territories. All other trademarks are property of their respective owners.